Ixekizumab for treating axial spondyloarthritis – guidance (TA718)

NICE recommends ixekizumab as an option for insufficiently controlled active ankylosing spondylitis (AS), or active non-radiographic AS with signs of inflammation, in specified circumstances in adults.

SPS commentary:

Treatment should be assessed at 16-20 weeks, and treatment only continued if there is clear evidence of response, defined as: a reduction in BASDAI score to 50% baseline or by 2 or more units, and a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more.

National Institute for Health and Care Excellence